Multidisciplinary approach for biliary tract cancer after progression to first-line therapy with gemcitabine and cisplatin: post-progression survival and safety outcomes

Background Patients with unresectable biliary tree cancer (uBTC) progressing despite first-line treatment with gemcitabine plus cisplatin (GC) have limited systemic options with modest survival benefit. Data on efficacy and safety of a personalized treatment based on a multidisciplinary discussion for patients with progressing uBTC are lacking.